Name (Synonyms) | Correlation | |
---|---|---|
drug918 | QFR Wiki | 0.71 |
drug63 | Angiography Wiki | 0.71 |
drug1233 | Vitamins Wiki | 0.71 |
drug1135 | Telmisartan Wiki | 0.50 |
drug431 | Favipiravir Wiki | 0.22 |
drug865 | Placebo oral tablet Wiki | 0.14 |
drug505 | Hydroxychloroquine Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D007511 | Ischemia NIH | 0.71 |
D023921 | Coronary Stenosis NIH | 0.71 |
D003327 | Coronary Disease NIH | 0.50 |
D003324 | Coronary Artery Disease NIH | 0.41 |
D009203 | Myocardial Ischemia NIH | 0.35 |
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0005145 | Coronary artery stenosis HPO | 0.71 |
HP:0001677 | Coronary artery atherosclerosis HPO | 0.41 |
HP:0001658 | Myocardial infarction HPO | 0.35 |
There are 2 clinical trials
This trial will estimate the efficacy and tolerance of several experimental treatments to prevent hospitalization or death in outpatients aged 65 years or above with Symptomatic SARS-CoV-2 Infection (COVID-19).
Description: Proportion of participants with an occurrence of death
Measure: Death Time: From inclusion (day0) to day 14Description: Proportion of deaths, overall and by cause, in each group
Measure: Death and causes of death Time: From inclusion (day0) to day 28Description: Evolution of Haematological markers in each group : Complete Blood Count, prothrombin level, INR
Measure: Haematological markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Evolution of Biochemical markers in each group : ferritin, serum creatinine, urea, sodium, potassium, chlorine, calcium, magnesium, albumin, bicarbonates / tCO2, LDH, CPK, ASAT, ALAT, uricemia
Measure: Biochemical markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Evolution of Inflammatory markers in each group : PCT, CRP
Measure: Inflammatory markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Evolution of immunological markers in each group : B ans T Cells phenotypic profiles
Measure: Immunological markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Number and proportion of grade 1,2,3,4 adverse events in each group
Measure: Adverse events Time: from inclusion (day 0) to day 14Description: Number and proportion of grade 1,2,3,4 adverse events in each group
Measure: Adverse reactions Time: from inclusion (day 0) to day 14Description: Plasma concentration of the study drugs at D7
Measure: Plasma concentration Time: day 7Description: Acceptability of the treatment by participant will be assessed with an interview
Measure: Acceptability of the treatment Time: from inclusion (day 0) to day 10This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Description: The ordinal scale is an evaluation of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Measure: The proportion of patients with a two-point change using the 8-category ordinal scale Time: Day 14 from baselineDescription: All-cause mortality post baseline
Measure: All-Cause mortality Time: Day 28 and Day 60 post baselineDescription: Time to a 2-point clinical change difference
Measure: Time to a 2-point clinical change Time: Up to 60 days post baselineDescription: Duration of hospitalization
Measure: Hospitalization Time: Up to 60 days post baselineDescription: For subjects who are on ECMO or mechanical ventilation at Day 1
Measure: Duration of ECMO or invasive mechanical ventilation Time: Up to 60 days post baselineDescription: For subjects who are in ICU at Day 1
Measure: Duration of ICU stay Time: Up to 60 days post baselineDescription: Time to SARS-CoV-2 negative by reverse transcriptase-polymerase chain reaction (RT-PCR)
Measure: SARS-CoV-2 negative Time: Up to 60 days post baselineDescription: Proportion of patients with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT PCR on days 5, 10, 14, 21, and 28 after starting treatment
Measure: Negative oropharyngeal or nasopharyngeal swab Time: Up to 28 days post baselineDescription: Proportion of subjects with serious adverse events
Measure: Serious adverse events (SAEs) Time: Up to 60 days post baselineDescription: Proportion of subjects who discontinue study drug due to adverse events
Measure: Discontinuation due to adverse events Time: Up to 60 days post baseline